Nuhou Uea

Ke hoʻohiki nei i nā lāʻau lapaʻau mua no ka maʻi maʻi ʻōpū/GEJ

i kakauia ma hoʻoponopono

Ua hoʻolaha ʻo Trishula Therapeutics, Inc. i kēia lā i nā hopena mua mai ka hoʻāʻo ʻana o ka Phase 1 e loiloi ana i ka TTX-030 i hui pū ʻia me budigalimab (ʻimi noiʻi anti-PD-1) a me FOLFOX no ka lāʻau lapaʻau mua o nā maʻi me ka maʻi maʻi / metastatic HER2 maikaʻi ʻole a i ʻole. maʻi maʻi ʻaʻai maʻi maʻi gastroesophageal junction. Ua hōʻike ʻia nā hopena haʻawina ma kahi hōʻike waha ma ka Hui ʻAmelika Hui Pū ʻIa no Cancer Research (AACR) Annual Meeting ma New Orleans. Hōʻike ka ʻikepili i hōʻike ʻia ua ʻae maikaʻi ʻia ka lāʻau hui pū ʻana o TTX-030 a hōʻike i nā hōʻailona hoʻoikaika o ka hana anti-tumor.

"ʻO nā pane pane me nā maʻi me ka PD-L1 haʻahaʻa haʻahaʻa i ʻike ʻia i kēia loiloi mua he mea hoʻoikaika nui a kākoʻo i ka hiki o TTX-030 e hoʻopilikia i ke kūlana o ka mālama ʻana i nā maʻi me ka maʻi maʻi gastric a me gastroesophageal," wahi a Zev Wainberg, MD, Polofesa o ka Lapaʻau ma UCLA a me ka luna alakaʻi o ka UCLA GI Oncology Program. "Ke kakali nei mākou i nā ʻike piha mai kēia hoʻokolokolo a me ka holomua hou ʻana o kēia ala lapaʻau hoʻohiki."

Ua hōʻike ʻia ka hopena mua a me nā hopena palekana e like me ka ʻoki ʻana i ka ʻikepili interim o Malaki 1, 2022. He 44 mau mea maʻi i kākau inoa ʻia. He iwakāluakūmāono (26) nā mea maʻi i hoʻopaʻa ʻia, a ʻo ka lōʻihi o ke aʻo ʻana he 214 mau lā (ma waena o 8-464+ mau lā). Ma waena o 40 mau mea maʻi i hiki ke loiloi ʻia, ua loaʻa i nā maʻi 21 (25 mau maʻi me ka ʻole i hōʻoia ʻia) i loaʻa i ka pane holoʻokoʻa maikaʻi loa o ka pane hapa a ʻoi aku ka maikaʻi me 4 CRs: ORR = 52.5% (62,5% me ka hōʻoia ʻole ʻia), a me ka helu hoʻomalu maʻi = 92.5%. He kanakolukumamāhiku (37) o ka poʻe maʻi i ʻike i ka PD-L1 Combined Positive Score (CPS); ʻO nā pane pane i nā maʻi me CPS ≥1 he 65% (77% me ka hōʻoia ʻole).

He iwakāluakūmāhiku o nā maʻi 44 (61%) i loaʻa ma kahi o hoʻokahi hanana ʻino (AE) o kēlā me kēia papa i manaʻo ʻia e pili ana me TTX-030 (nā mea noiʻi loiloi), me 9 mau maʻi (20.5%) me ka Papa 3/4 AE. Ua kūlike nā hanana ʻino me nā mea i ʻike ʻia me ka mālama maʻamau (chemotherapy me anti-PD-1).

"ʻO kā mākou ʻikepili i hōʻike ʻia ma AACR e hōʻike ana i ka ʻike mua o ka lāʻau anti-CD39 antibody i nā maʻi me nā maʻi maʻi ʻōpū a kākoʻo i ka hana o TTX-030 i ka hoʻohuli ʻana i ka immunosuppression adenosine-mediated," wahi a Anil Singhal, Luna Nui. "Ke kali nei mākou i ka holomua o kēia noiʻi lapaʻau o TTX-030, a mākou e manaʻoʻiʻo nei he hiki ke hoʻomaikaʻi nui i ka paradigm lapaʻau no nā maʻi maʻi maʻi."

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

Kaʻana like i...